Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

December 1, 2010 updated by: AstraZeneca
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Anticipated)

8000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hong Kong
      • Hong Kong, Hong Kong, China
        • Research Site
  • Indonesia
    • Central Java
      • Semarang, Central Java, Indonesia
        • Research Site
    • DKI Jakarta
      • Jakarta, DKI Jakarta, Indonesia
        • Research Site
    • East Java
      • Sidoarjo, East Java, Indonesia
        • Research Site
      • Surabaya, East Java, Indonesia
        • Research Site
    • North Sumatra
      • Medan, North Sumatra, Indonesia
        • Research Site
    • West Java
      • Bandung, West Java, Indonesia
        • Research Site
  • Korea, Republic of
      • Bu-san, Korea, Republic of
        • Research Site
      • Dae-gu, Korea, Republic of
        • Research Site
      • Dae-jeon, Korea, Republic of
        • Research Site
      • Gwangju, Korea, Republic of
        • Research Site
      • In-cheon, Korea, Republic of
        • Research Site
      • Je-ju, Korea, Republic of
        • Research Site
      • Seoul, Korea, Republic of
        • Research Site
      • Ul-san, Korea, Republic of
        • Research Site
    • Chung-Cheong-nam-do
      • Cheon-an, Chung-Cheong-nam-do, Korea, Republic of
        • Research Site
    • Gyeong-gi
      • Bu-cheon, Gyeong-gi, Korea, Republic of
        • Research Site
      • Bundang, Gyeong-gi, Korea, Republic of
        • Research Site
      • Gu-ri, Gyeong-gi, Korea, Republic of
        • Research Site
      • Il-san, Gyeong-gi, Korea, Republic of
        • Research Site
      • Su-won, Gyeong-gi, Korea, Republic of
        • Research Site
    • Gyung-sang-nam-do
      • Ma-san, Gyung-sang-nam-do, Korea, Republic of
        • Research Site
  • Malaysia
      • Kuala Lumpur, Malaysia
        • Research Site
      • Selangor, Malaysia
        • Research Site
    • Kuala Lumpur
      • Bangsar, Kuala Lumpur, Malaysia
        • Research Site
      • Kepong, Kuala Lumpur, Malaysia
        • Research Site
      • Puchong, Kuala Lumpur, Malaysia
        • Research Site
      • Setapak, Kuala Lumpur, Malaysia
        • Research Site
    • Selangor
      • Ampang, Selangor, Malaysia
        • Research Site
      • Bandar Sunway, Selangor, Malaysia
        • Research Site
      • Batu Caves, Selangor, Malaysia
        • Research Site
      • Hulu Selangor, Selangor, Malaysia
        • Research Site
      • Klang, Selangor, Malaysia
        • Research Site
      • Petaling Jaya, Selangor, Malaysia
        • Research Site
      • Port Klang, Selangor, Malaysia
        • Research Site
      • Sekinchan, Selangor, Malaysia
        • Research Site
      • Seri Kembangan, Selangor, Malaysia
        • Research Site
      • Shah Alam, Selangor, Malaysia
        • Research Site
      • Subang, Selangor, Malaysia
        • Research Site
      • Subang Jaya, Selangor, Malaysia
        • Research Site
      • Sungai Buloh, Selangor, Malaysia
        • Research Site
  • Philippines
      • Davao, Philippines
        • Research Site
      • Iloilo, Philippines
        • Research Site
      • Manila, Philippines
        • Research Site
    • Batangas
      • Lipa, Batangas, Philippines
        • Research Site
    • Benguet
      • Baguio, Benguet, Philippines
        • Research Site
  • Taiwan
      • Kaohsiung, Taiwan
        • Research Site
      • Taichung, Taiwan
        • Research Site
      • Tainan, Taiwan
        • Research Site
      • Taipei, Taiwan
        • Research Site
      • Taoyuan, Taiwan
        • Research Site
  • Thailand
    • Bangkok
      • Bangkoknoi, Bangkok, Thailand
        • Research Site
      • Dusit, Bangkok, Thailand
        • Research Site
      • Pathumwan, Bangkok, Thailand
        • Research Site
      • Ratchathewi, Bangkok, Thailand
        • Research Site
    • ChiangMai
      • Muang, ChiangMai, Thailand
        • Research Site
    • Pathumthani
      • Klongluang, Pathumthani, Thailand
        • Research Site
  • Vietnam
      • Hanoi, Vietnam
        • Research Site
      • Hcmc, Vietnam
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Description

Inclusion Criteria:

  • 2 or more risk factors (according to NCEP ATP III guideline)
  • Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion Criteria:

  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study.
  • Participation in a clinical study during the last 90 days.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country)
Time Frame: After collecting all Patient Record Form.
After collecting all Patient Record Form.

Secondary Outcome Measures

Outcome Measure
Time Frame
The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets.
Time Frame: After collecting all Patient Record Form.
After collecting all Patient Record Form.
The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables.
Time Frame: After collecting all Patient Record Form.
After collecting all Patient Record Form.
The physician characteristics associated with the allocation of hypercholesterolemia treatment regime.
Time Frame: After collecting all Patient Record Form.
After collecting all Patient Record Form.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Principal Investigator: Park Jeong Euy, Sungkyunkwan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2008

Primary Completion (Actual)

December 1, 2008

Study Completion (Actual)

December 1, 2008

Study Registration Dates

First Submitted

May 28, 2008

First Submitted That Met QC Criteria

May 29, 2008

First Posted (Estimate)

May 30, 2008

Study Record Updates

Last Update Posted (Estimate)

December 2, 2010

Last Update Submitted That Met QC Criteria

December 1, 2010

Last Verified

December 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-CAP-DUM-2008/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypercholesterolemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe